Status:

NOT_YET_RECRUITING

Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia

Lead Sponsor:

Ruijin Hospital

Conditions:

Dementia

Eligibility:

All Genders

60-80 years

Phase:

PHASE1

PHASE2

Brief Summary

This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and ...

Eligibility Criteria

Inclusion

  • Participants must be aged 60 to 80 years (inclusive) at the time of screening, regardless of gender.
  • Participants must have a Clinical Dementia Rating (CDR) total score \> 1, indicating moderate to severe dementia.
  • Participants must provide written informed consent to participate in the study.

Exclusion

  • Presence of other neurological diseases that may cause cognitive decline, such as cerebrovascular disease, encephalitis, brain tumors, traumatic brain injury, epilepsy, Parkinson's disease, etc.
  • Presence of metabolic diseases that may cause cognitive decline, such as anemia, thyroid dysfunction, folate and vitamin B12 deficiency, etc.
  • Presence of severe psychiatric disorders, such as major depression.
  • History of carbon monoxide poisoning.
  • Presence of acute or severe life-threatening diseases.
  • Presence of severe visual, auditory, or language impairments that would prevent the completion of neuropsychological assessments.
  • Current use of psychotropic medications or a history of substance abuse.
  • Individuals with specific allergy histories, or those with a history of allergies to two or more medications, foods (such as milk), or pollen (excluding untreated, asymptomatic seasonal allergies), or known allergies to components of the study drug or similar agents.

Key Trial Info

Start Date :

August 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 31 2026

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06946511

Start Date

August 1 2025

End Date

January 31 2026

Last Update

May 1 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200025

2

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200025